静脉阿替普酶对缺血性卒中后24-48小时缺血性脑病灶的影响
IST-3随机对照试验纳入2916例有基线和随访影像的缺血性卒中患者,评估静脉阿替普酶对24-48小时脑影像缺血病灶的影响。阿替普酶组较对照组减少病灶可见度增加(OR=0.77),但未减少病灶范围或水肿进展。6项试验荟萃分析(n=4757)显示阿替普酶与随访影像缺血病灶范围缩小相关(OR=0.85)。
要点
- 病灶范围或水肿进展独立预测6个月功能结局较差(OR=0.92和OR=0.73)。
- 阿替普酶组较对照组减少随访时病灶可见度增加(OR=0.77,95%CI 0.67-0.89)。
- 荟萃分析6项试验显示阿替普酶与随访影像病灶范围缩小相关(OR=0.85,95%CI 0.76-0.95)。
核心结论
- 阿替普酶与短期病灶可见度进展减少相关;荟萃分析中阿替普酶减少病灶范围,可能通过减少组织损伤改善功能结局。
研究设计与样本
- IST-3为静脉阿替普酶治疗缺血性卒中的随机对照试验,3035例入组患者中2916例有基线和随访脑影像。
- 对阿替普酶与对照的随机试验进行荟萃分析,纳入6项试验包括IST-3(n=4757),均有随机化前后影像。
主要发现
- 病灶范围进展独立预测6个月结局较差(校正OR=0.92,95%CI 0.88-0.96,p<0.001)。
- 水肿进展独立预测6个月结局较差(校正OR=0.73,95%CI 0.66-0.79,p<0.001)。
- 阿替普酶组较对照组减少随访时病灶可见度增加(OR=0.77,95%CI 0.67-0.89,p<0.001)。
- 无证据表明阿替普酶减少病灶范围或水肿进展。
- 荟萃分析中阿替普酶与随访影像缺血病灶范围缩小相关(OR=0.85,95%CI 0.76-0.95,p=0.004)。
关键数值与推荐
- 本研究提供II级证据表明静脉阿替普酶阻碍卒中后影像上缺血性脑病灶的进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether alteplase alters the development of ischemic lesions on brain imaging after stroke. METHODS: The Third International Stroke Trial (IST-3) was a randomized controlled trial of IV alteplase for ischemic stroke. We assessed CT or brain MRI at baseline (pretreatment) and 24 to 48 hours posttreatment for acute lesion visibility, extent, and swelling, masked to all other data. We analyzed associations between treatment allocation, change in brain tissue appearances between baseline and follow-up imaging, and 6-month functional outcome in IST-3. We performed a meta-analysis of randomized trials of alteplase vs control with pre- and postrandomization imaging. RESULTS: Of 3,035 patients recruited in IST-3, 2,916 had baseline and follow-up brain imaging. Progression in either lesion extent or swelling independently predicted poorer 6-month outcome (adjusted odds ratio [OR] = 0.92, 95% confidence interval [CI] 0.88-0.96, p < 0.001; OR = 0.73, 95% CI 0.66-0.79, p < 0.001, respectively). Patients allocated alteplase were less likely than controls to develop increased lesion visibility at follow-up (OR = 0.77, 95% CI 0.67-0.89, p < 0.001), but there was no evidence that alteplase reduced progression of lesion extent or swelling. In meta-analysis of 6 trials including IST-3 (n = 4,757), allocation to alteplase was associated with a reduction in ischemic lesion extent on follow-up imaging (OR = 0.85, 95% CI 0.76-0.95, p = 0.004). CONCLUSION: Alteplase was associated with reduced short-term progression in lesion visibility. In meta-analysis, alteplase reduced lesion extent. These findings may indicate that alteplase improves functional outcome by reducing tissue damage. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that IV alteplase impedes the progression of ischemic brain lesions on imaging after stroke.
引用
- Mair G, von Kummer R, Morris Z, et al. Effect of IV alteplase on the ischemic brain lesion at 24-48 hours after ischemic stroke. Neurology. 2018. PMID: 30366975. doi:10.1212/WNL.0000000000006575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。